EP0105481A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel antigens and vaccines containing them
Assignee: Wellcome Foundation Ltd
•
Filing: 1983-09-29
•
Granted: —
•
Expires: 2003-09-29
Abstract
Abstract Novel antigenic peptides effective in stimulating immunity to foot and mouth disease virus (FMDV) are disclosed, together with methods for their preparation, vaccines containing the peptides and to their use in the prophylaxis of FMDV.
Inventors
- 👤 John Charles Boothroyd
- 👤 Andrew Joseph Makoff
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 19:13
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; A61K39/12; A61K39/125; A61K39/135; A61K38/00; C12; C12N; C12N2770/00; C12N2770/00011; C12N2770/32011; C12N2770/32111; C12N2770/32122; C12N2770/32134
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
37 words
A peptide characterised in that it comprises the amino acid sequence of an antiqenic site of a VP q protein selected from serotypes A24 Cruzeiro, C 3 Indaial or O 1 BFS, fraqments thereof and derivatives thereof.
Claim 2
Dependent Claim
37 words
A peptide characterised in that it comprises the amino acid sequence of an antiqenic site of a VP q protein selected from serotypes A24 Cruzeiro, C 3 Indaial or O 1 BFS, fraqments thereof and derivatives thereof.
Claim 3
Dependent Claim
33 words
A peptide as claimed in claim 1 characterised in that it corresponds to all or part of a reqion of VP,, selected from 42-61; 79-85; 95-102; 129-160 (or 162); 170-176; 193-204 (or 206).
Claim 4
Dependent Claim
32 words
A peptide as claimed in either claim 1 or claim 2 characterised in that it corresponds to a reqion of VP 1 selected from 79-85; 129-160 (or 162) and 193-204 (or 209).
Claim 5
Dependent Claim
31 words
A peptide as claimed in any one of claims 1 to 3 characterised in that it corresponds to a reqion of VP 1 selected from 42-51; 56-61; 129-147; 151-160 and 143-162.
Claim 6
Dependent Claim
22 words
A peptide as claimed in any one of claims 1 to 4 and selected from:- 6. The peptide havinq the sequence GSGRRGDMGSLAARVVKQLP.
Claim 7
Dependent Claim
6 words
The peptide havinq the sequence NLRGDLQVLAQKVARTLP.
Claim 8
Dependent Claim
6 words
The peptide havinq the sequence NLRGDLQVLAQKVARTLP.
Claim 9
Dependent Claim
25 words
A protein havinq the structure of VP 1 of FMDV serotypes A24 Cruzeiro, C 3 Indaial or O 1 BFS as shown in Fiqure 3.
Claim 10
Dependent Claim
25 words
A protein havinq the structure of VP 1 of FMDV serotypes A24 Cruzeiro, C 3 Indaial or O 1 BFS as shown in Fiqure 3.
Claim 11
Dependent Claim
20 words
An immunoqen comrisinq a p eptIde as defined in any one of claims 1 to 8 linked to a carrier.
Claim 12
Dependent Claim
30 words
A vaccine comprising a peptide as defined in any one of claims 1 to 8 or an immunoqen as defined in claim 9 together with a pharmaceutically acceptable vehicle therefor.
Claim 13
Independent Claim
132 words
A method of preparinq a peptide or protein as defined in any one of claims 1 to 8 comprisinq:- A. Synthetic preparation by known techniques from individual amino acids, from linking of smaller peptides or a combination thereof; B. Cleavage, and, optionally subsequent modification, of larqer polypeptides or proteins; or C. (a) transforminq a host cell with recombinant DNA, said recombinant DNA comprisinq (1) a doubled, stranded DNA sequence codinq for or includinq a sequence codinq for a protein or for a peptide as defined in any one of claims 1 to 8 (2) a cloninq vehicle DNA sequence and (3) initiator and terminator sequences for expression of DNA; (b) culturinq the host cell under conditions suitable for expression of FMD peptide; (c) harvestinq the cell culture, and (d) separatinq said peptide
Claim 14
Dependent Claim
47 words
A DNA molecule comprisinq a nucleotide sequence for a protein or peotide as defined in any one of claims 1 to 8 or a DNA molecule codinq for a polypeptide which polypeptide includes a peptide or protein as defined in any one of claims 1 to 8.
Claim 15
Dependent Claim
57 words
A recombinant DNA molecule comprising an operon having initiator sequences as herein defined, and a nucleotide sequence substantially coding for protein or peptide as defined in any one of claims 1 to 8 or a nucleotide sequence including such a sequence, the nucleotide sequence being located between the initiator sequences and the terminator sequences of the operon.
Claim 16
Dependent Claim
61 words
A recombinant DNA cloning vehicle capable of expressing all or part of a protein or peptide as defined in any one of claims 1 to 8 comprising an operon having initiator sequences and terminator sequences, and a nucleotide sequence substantially coding for said peptide or protein the nucleotide sequence being located between the initiator sequences and terminator sequences of the operon.
Claim 17
Dependent Claim
24 words
A host cell containing a recombinant DNA cloning vehicle and/or a recombinant DNA molecule as defined in any one of claims 12 to 14.
Claim 18
Dependent Claim
72 words
An antigen for stimulating the production of antibodies against FMDV in a mammal comprising a protein or a peptide as defined in any one of claims 1 to 8 prepared by the expression of a DNA molecule as hereinbefore defined and produced by a host cell transformed with a recombinat DNA cloning vehicle as hereinbefore defined and produced by a host cell transformed with a recombinant DNA cloning vehicle as hereinbefore defined.
Claim 19
Independent Claim
73 words
A method of preparing a DNA molecule substantially coding for a peptide as defined in any one of claims 1 to 8 comprising (a) isolating FMDV single stranded RNA; (b) preparing a first single strand of DNA complementary to the single strand of FMDV RNA; and (c) preparing a second single strand of DNA complementary to and hydrogen bonded to the first DNA strand so as to produce a double strand of DNA.
Claim 20
Dependent Claim
18 words
A peptide or protein as defined in any one of claims 1 to 8 for use in therapy.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.